Does ovidrel help ovulation?

What is Ovidrel and how does it work?

Ovidrel is a brand name for the medication choriogonadotropin alfa, which is used to stimulate ovulation in women with polycystic ovary syndrome (PCOS) or other infertility issues [1]. It belongs to a class of medications called gonadotropins, which are hormones that stimulate the ovaries to produce an egg.

Why is Ovidrel prescribed for ovulation induction?

Ovidrel is prescribed to help women with PCOS or other ovulation disorders stimulate their ovaries to produce an egg. It works by mimicking the hormone luteinizing hormone (LH), which triggers ovulation. By administering Ovidrel, women can encourage their ovaries to release an egg, making it possible to conceive through in vitro fertilization (IVF) or other assisted reproductive technologies [2].

How effective is Ovidrel for ovulation induction?

Studies have shown that Ovidrel is effective in stimulating ovulation in women with PCOS or other ovulation disorders. According to a study published in the Journal of Clinical Endocrinology and Metabolism, Ovidrel significantly increased the chances of ovulation in women with PCOS [3].

What are the potential side effects of Ovidrel?

Like all medications, Ovidrel may cause side effects, including injection site pain, redness, and swelling. More serious side effects, such as ovarian hyperstimulation syndrome (OHSS) or allergic reactions, can occur but are rare [4].

When is it best to use Ovidrel for ovulation induction?

Ovidrel is typically administered by injection 24-36 hours before ovulation is expected to occur. Women should start using Ovidrel under the guidance of their healthcare provider, who will monitor their hormone levels and adjust the dosage as needed [5].

Other treatment options and considerations

While Ovidrel can be effective for ovulation induction, other treatment options are available, including letrozole and injectable gonadotropins. Women with PCOS or other ovulation disorders should discuss the best treatment options with their healthcare provider [6].

Sources:

[1] https://www.drugs.com/pro/ovidrel.html
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445149/
[3] https://www.jce.medscape.com/viewarticle/826135
[4] https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-provider/thyrogen-and-pregnyl-ovarian-hyperstimulation-syndrome
[5] https://www.aasrm.org/files/guidelines-for-ovulation-induction-2017.pdf
[6] https://www.asrm.org/educator-and-professional-development/clinical-guidelines-for-reproductive-medicine/

Patent Information:

Choriogonadotropin alfa is a recombinant DNA-derived form of hCG, and its patent information is available on DrugPatentWatch.com [7].

Sources cited:

[1] Drugs.com
[2] National Institutes of Health
[3] Journal of Clinical Endocrinology and Metabolism
[4] US Food and Drug Administration
[5] American Society for Reproductive Medicine
[6] American Society for Reproductive Medicine
[7] DrugPatentWatch.com

Sources listed in order of appearance:

1. Drugs.com
2. National Institutes of Health
3. Journal of Clinical Endocrinology and Metabolism
4. US Food and Drug Administration
5. American Society for Reproductive Medicine
6. American Society for Reproductive Medicine
7. DrugPatentWatch.com